All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Zytorvi 240mg Injection
Prescription Required
Salt Composition : Toripalimab
Manufacturer : DR REDDY'S LABORATORIES LTD
Origin of Medicine : India
1 Vial(s)
Introduction to Zytorvi 240mg Injection
Zytorvi 240mg Injection contains the active ingredient Toripalimab. It is a monoclonal antibody used in the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC). It is administered as a first-line therapy in combination with cisplatin and gemcitabine for adult patients and as a single agent for those with recurrent, unresectable, or metastatic NPC that has progressed after platinum-based chemotherapy.
Zytorvi 240mg Injection works by blocking the PD-1 receptor, preventing its interaction with the PD-L1 and PD-L2 ligands. This action lifts the inhibition on T cells, boosting their activity and enhancing immune surveillance, ultimately promoting an anti-tumour immune response. In preclinical models, PD-1 blockade demonstrated a reduction in tumour growth.
Zytorvi 240mg Injection is associated with common side effects, including nausea and vomiting, burning or tingling sensations in the feet and toes, decreased appetite, diarrhoea, and constipation. It carries warnings for severe immune-mediated adverse reactions, which may affect any organ or tissue and could be fatal. These reactions can occur at any time during treatment or even after discontinuation, requiring close monitoring and immediate medical intervention when necessary.
Also, infusion-related reactions such as hypersensitivity and anaphylaxis may occur during administration. For patients who have undergone or are undergoing allogeneic hematopoietic stem cell transplantation (HSCT), Zytorvi 240mg Injection may lead to serious complications such as graft-versus-host disease (GVHD) and other transplant-related issues. Zytorvi 240mg Injection is contraindicated during pregnancy due to the risk of fetal harm, including potential fetal death.
Uses of Zytorvi 240mg Injection
The uses of Zytorvi 240mg Injection are:
- First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) in combination with cisplatin and gemcitabine
- Single-agent treatment for adults with recurrent, unresectable, or metastatic NPC that has progressed after platinum-containing chemotherapy
Therapeutic Effects of Zytorvi 240mg Injection
Zytorvi 240mg Injection blocks the PD-1 receptor, preventing its interaction with the PD-L1 and PD-L2 ligands. This action stimulates T cells, enhancing their activity and restoring immune surveillance to promote an anti-tumour immune response. In preclinical models, blocking PD-1 activity reduced tumour growth.
Interaction of Zytorvi 240mg Injection with other drugs
It is important to inform your healthcare professional about all the medications you are taking, including prescription drugs, over-the-counter medications, nutritional supplements, and herbal products. Some medications may interact with Zytorvi 240mg Injection, potentially affecting their effectiveness or causing side effects.
More Information about Zytorvi 240mg Injection
- Keep out of reach of children and pets.
- Store in the original packaging to protect from moisture.
- Avoid direct sunlight
- Store Zytorvi 240mg Injection in a refrigerator at a temperature of 2°C to 8°C.
- Do not freeze or shake it.
How to consume Zytorvi 240mg Injection
Your healthcare provider administers Zytorvi 240mg Injection through an intravenous (IV) line into your vein over 30 to 60 minutes. It is usually given every two or three weeks as an IV infusion. Your healthcare provider will decide the number of treatments you need and monitor your blood for potential side effects. If you miss an appointment, contact your healthcare provider immediately to reschedule.
Safety Advices for Zytorvi 240mg Injection
Pregnancy
The Zytorvi 240mg Injection is not safe to use in pregnant women as it may cause fetal harm.
Breast Feeding
The Zytorvi 240mg Injection is not safe to use in breastfeeding women as it passes through breast milk.
Lungs
Before starting treatment with Zytorvi 240mg Injection talk to your doctor if you have any lung conditions.
Liver
You need to inform your doctor if you have any liver disorders before starting treatment with Zytorvi 240mg Injection.
Alcohol
It is unknown whether alcohol consumption is safe while you are undergoing Zytorvi 240mg Injection course. It is recommended to consult your doctor for better guidance.
Driving
Zytorvi 240mg Injection may have a minor influence on the ability to drive or handle machines as some patients reported dizziness and fatigue. It is recommended to consult your doctor for better guidance.
Side Effects of Zytorvi 240mg Injection
Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.
Common side effects of Zytorvi 240mg Injection are:
- Decreased appetite
- Nausea and vomiting
- Constipation and diarrhoea
- Muscle and bone pain
- Dizziness
- Burning or feeling of pins and needles in feet and toes
- Upper respiratory infection
- Sleep problems
- Rash
- Fever and cough
- Low levels of thyroid hormone
Serious side effects of Zytorvi 240mg Injection are:
- Severe allergic reactions such as difficulty breathing, swelling of face or throat
- Liver problems (e.g., yellowing of skin or eyes, dark urine)
- Lung problems (e.g., shortness of breath, cough, chest pain)
- Immune system problems leading to inflammation in organs
- Endocrine problems
- Severe infections
Word of Advice
Zytorvi 240mg Injection can cause severe and potentially fatal immune-mediated reactions, which may affect any organ and occur at any time during treatment or after discontinuation, requiring close monitoring. It may also cause infusion-related reactions, including severe hypersensitivity or anaphylaxis. Patients undergoing or planning HSCT should be aware of potential complications like graft-versus-host disease. Additionally, Zytorvi 240mg Injection can harm a developing fetus, so it should be avoided during pregnancy. Always follow your healthcare provider’s instructions and attend regular check-ups to manage any risks.
FAQs
Q 1. Is Zytorvi 240mg Injection FDA-approved?
Yes, the U.S. FDA approved Toripalimab, the active ingredient of Zytorvi 240mg Injection on October 27, 2023, for use in treating specific cancers.
Q 2. Is Zytorvi 240mg Injection effective?
Yes, Zytorvi 240mg Injection has been shown to be effective in treating certain cancers, particularly when combined with chemotherapy. Clinical trials demonstrate its ability to improve patient outcomes.
Q 3. Is Zytorvi 240mg Injection safe?
Zytorvi 240mg Injection is generally safe when used as prescribed, but it may cause immune-related side effects. Healthcare providers monitor patients closely to manage potential risks.
Q 4. What is the best time to take Zytorvi 240mg Injection?
Zytorvi 240mg Injection is administered by a healthcare provider through an intravenous infusion. The timing of each dose is determined by your treatment plan and healthcare provider's instructions.
Q 5. Who should not take Zytorvi 240mg Injection?
Zytorvi 240mg Injection should not be taken by individuals with a known hypersensitivity to the drug or any of its components. It is also not recommended for pregnant or breastfeeding women due to potential risks to the fetus or infant.
Fact Box of Zytorvi 240mg Injection
| Molecule name: Toripalimab | Therapeutic class: Immunotherapy |
| Pharmacological class: Monoclonal antibody | Indications: 1. First-line treatment for adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC) with cisplatin and gemcitabine. 2. Single-agent treatment for adults with recurrent, unresectable, or metastatic NPC after platinum-based chemotherapy. |
References
1. Wei XL, Ren C, Wang FH, Zhang Y, Zhao HY, Zou BY, Wang ZQ, Qiu MZ, Zhang DS, Luo HY, Wang F, Yao S, Xu RH. A phase I study of toripalimab, an anti-PD-1 antibody, in patients with refractory malignant solid tumors.
https://pubmed.ncbi.nlm.nih.gov/32589350/
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761240s000lbl.pdf
3. Zhang L, Hao B, Geng Z, Geng Q. Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China. https://pmc.ncbi.nlm.nih.gov/articles/PMC8789657/
4. https://www.ema.europa.eu/en/documents/product-information/loqtorzi-epar-product-information_en.pdf
Disclaimer
MrMed’s primary intention is to ensure that its consumers get accurate and trustworthy information that is reviewed by experts. The contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
